← Leaderboards
Paul Wentworth
Scripps Research Institute, The
$2,922,142
Attributed
$2,922,142
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $568.5K · FY2006–13$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$2,922,142 · 6
By mechanism
R21$2,922,142 · 6
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectProteinsCellsIn VivoAntibodiesAffinityPublic Health RelevanceProgramsVaccinesComplexBinding (Molecular Function)DesignBaseResponsePublic Health Medicine (Field)SerumPreventPeptidesOralPharmaceutical PreparationsPlasmaImmune SystemAmericasLibraries
Grant awards (12)
C3 Tumor Associated Carbohydrate Antigen Bioconjugates$236,875
R21 · FY2013 · AI · contact PI
C3 Tumor Associated Carbohydrate Antigen Bioconjugates$284,250
R21 · FY2012 · AI · contact PI
C3 chemical conjugation to improve the anti-cocaine immune response$284,250
R21 · FY2012 · DA · contact PI
C3 chemical conjugation to improve the anti-cocaine immune response$236,875
R21 · FY2011 · DA · contact PI
Lactobacilli surface antibody expression for in vivo protection against cholera$235,001
R21 · FY2011 · AI · contact PI
Lactobacilli surface antibody expression for in vivo protection against cholera$284,850
R21 · FY2010 · AI · contact PI
Beauveriolide-Derived Cyclodepsipeptides as a New Class of Anti-Alzheimer's Drugs$199,752
R21 · FY2010 · AG · contact PI
Beauveriolide-Derived Cyclodepsipeptides as a New Class of Anti-Alzheimer's Drugs$242,123
R21 · FY2009 · AG · contact PI
Antibody Generation of ROS and Macular Degeneration$225,636
R21 · FY2007 · EY · contact PI
Investigating the link between the atheronals and aging$185,023
R21 · FY2007 · AG · contact PI
Antibody Generation of ROS and Macular Degeneration$278,850
R21 · FY2006 · EY · contact PI
Investigating the link between the atheronals and aging$228,657
R21 · FY2006 · AG · contact PI